Clinical Trials Directory

Trials / Unknown

UnknownNCT02031367

Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome

Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
C.R.Darnall Army Medical Center · Federal
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The object of this study is to compare the effect of PRP versus Corticosteroid injection on pain in patients with Greater Trochanteric Pain Syndrome up to 12 months after treatment. It is believed that PRP will be as good as corticosteroids for short term pain relief, and will produce longer lasting pain reduction.

Detailed description

The purpose of this study is to compare the efficacy of Platelet Rich Plasma (PRP) injections versus Corticosteroid injections in treating patients that have failed noninvasive management for Greater Trochanteric Pain Syndrome (GTPS). We will be comparing in both the short term (0-6 months) and in the long term (6-12 months). It will be a Double-Blinded Randomized Clinical Trial. Patients with GTPS will be randomly assigned to either the Corticosteroid group or PRP group. There will be a total of 50 participants enrolled with 25 in each group. The PRP group will receive 3 mL of autologous plasma injection into the area of tendinopathy utilizing ultrasound guidance. One (1) injection per month will be administered for a total of three (3) injections. The Corticosteroid Group will receive 2.0 mL's injection of lidocaine and 40mg of Triamcinolone into the area of tendinopathy utilizing ultrasound guidance on their first injection. They will then receive 2.0 mL's of 1% lidocaine and 3.0 mL's of 0.9% Sodium Chloride per month for a total of three (3) injections. Both groups will be referred to physical therapy. Participant's pain will be assessed using a Visual Analog Scale (VAS) and the Nonarthritic Hip Score (NHS) for function at the beginning of the treatment and then again at 1, 3, 6, 9, and 12 months after the initial injection.

Conditions

Interventions

TypeNameDescription
DRUGTriamcinolone AcetonideCorticosteroid arm
OTHERPlatelet Rich PlasmaPlatelet Rich Plasma

Timeline

Start date
2014-03-01
Primary completion
2016-12-01
Completion
2016-12-01
First posted
2014-01-09
Last updated
2014-01-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02031367. Inclusion in this directory is not an endorsement.